Trevi TherapeuticsTRVI
TRVI
About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Employees: 27
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2,417% more call options, than puts
Call options by funds: $453K | Put options by funds: $18K
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
21% more funds holding
Funds holding: 77 [Q2] → 93 (+16) [Q3]
11% more capital invested
Capital invested by funds: $175M [Q2] → $194M (+$18.9M) [Q3]
3.4% less ownership
Funds ownership: 83.47% [Q2] → 80.07% (-3.4%) [Q3]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
48%
upside
Avg. target
$12.70
214%
upside
High target
$21
419%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 37 / 149 met price target | 419%upside $21 | Buy Maintained | 16 Dec 2024 |
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target | 85%upside $7.50 | Buy Reiterated | 13 Dec 2024 |
Needham Serge Belanger 40% 1-year accuracy 50 / 126 met price target | 98%upside $8 | Buy Reiterated | 12 Dec 2024 |
EF Hutton Jason Kolbert 25% 1-year accuracy 37 / 149 met price target | 419%upside $21 | Buy Maintained | 7 Nov 2024 |
B. Riley Securities Mayank Mamtani 35% 1-year accuracy 8 / 23 met price target | 48%upside $6 | Buy Reiterated | 7 Oct 2024 |
Financial journalist opinion
Based on 4 articles about TRVI published over the past 30 days
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
NEW HAVEN, Conn. , Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share, for total proceeds of $50 million, before deducting underwriting discounts and commissions and expenses payable by Trevi.
Positive
Benzinga
1 week ago
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
On Thursday, Trevi Therapeutics, Inc. TRVI announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160).
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, which requires no change to the current sample size for the trial (N=160).
Neutral
PRNewsWire
2 weeks ago
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p .m.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Corporate presentation will be held on Wednesday, December 4, 2024, at 1:00 p.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
2 months ago
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025.
Neutral
PRNewsWire
2 months ago
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
NEW HAVEN, Conn. , Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November.
Neutral
PRNewsWire
2 months ago
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs.
Charts implemented using Lightweight Charts™